JP2022550174A5 - - Google Patents
Info
- Publication number
- JP2022550174A5 JP2022550174A5 JP2022519804A JP2022519804A JP2022550174A5 JP 2022550174 A5 JP2022550174 A5 JP 2022550174A5 JP 2022519804 A JP2022519804 A JP 2022519804A JP 2022519804 A JP2022519804 A JP 2022519804A JP 2022550174 A5 JP2022550174 A5 JP 2022550174A5
- Authority
- JP
- Japan
- Prior art keywords
- therapeutic
- compound
- diagnostic
- dextran
- skeleton
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962908136P | 2019-09-30 | 2019-09-30 | |
| US62/908,136 | 2019-09-30 | ||
| PCT/US2020/053604 WO2021067479A1 (en) | 2019-09-30 | 2020-09-30 | Compositions and related methods for blocking off-target localization of mannosylated dextrans and other cd206 ligands |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022550174A JP2022550174A (ja) | 2022-11-30 |
| JP2022550174A5 true JP2022550174A5 (https=) | 2023-09-28 |
| JP7599727B2 JP7599727B2 (ja) | 2024-12-16 |
Family
ID=75337533
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022519804A Active JP7599727B2 (ja) | 2019-09-30 | 2020-09-30 | マンノシル化デキストラン治療用または診断用化合物の標的特異性を高めるためのキット |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20210145989A1 (https=) |
| EP (1) | EP4021459A4 (https=) |
| JP (1) | JP7599727B2 (https=) |
| CN (1) | CN115151264B (https=) |
| CA (1) | CA3155675A1 (https=) |
| MX (1) | MX2022003699A (https=) |
| WO (1) | WO2021067479A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3192041A1 (en) * | 2020-08-21 | 2022-02-24 | Resolute Science, Inc. | Compositions and methods for targeting tumor-associated macrophages |
| EP4472643A1 (en) * | 2022-02-04 | 2024-12-11 | Navidea Biopharmaceuticals, Inc. | Altering net charge on mannosylated dextrans to maximize target tissue uptake and off target competitive blocking |
| US20230302041A1 (en) * | 2022-03-25 | 2023-09-28 | Navidea Biopharmaceuticals, Inc. | Competitive Self-Blocking with Unlabeled Manocept Imaging Agents |
| CN114894698B (zh) * | 2022-04-15 | 2023-02-03 | 广东省第二人民医院（广东省卫生应急医院） | MDSCs在再生障碍性贫血诊断和/或分型中的应用 |
| EP4554984A1 (en) * | 2022-07-13 | 2025-05-21 | Navidea Biopharmaceuticals, Inc. | Mannosylated amine dextran drug delivery vehicles with degradable disulfide/carbonate linkers targeting payloads to cd206 expressing cells |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4624046A (en) * | 1982-01-04 | 1986-11-25 | Fairchild Camera & Instrument Corp. | Oxide isolation process for standard RAM/PROM and lateral PNP cell RAM |
| US4624846A (en) * | 1983-07-29 | 1986-11-25 | Immunomedics, Inc. | Method for enhancing target specificity of antibody localization and clearance of non-target diagnostic and therapeutic principles |
| JP3582234B2 (ja) * | 1996-05-20 | 2004-10-27 | ニプロ株式会社 | ＩｇＡ腎症特異的フィブロネクチン断片、その検出方法およびキット |
| EP1178838B1 (en) * | 1999-05-14 | 2004-09-29 | The Regents of the University of California | Macromolecular carrier based on dextran for drug and diagnostic agent delivery |
| US20050169883A1 (en) * | 2002-05-06 | 2005-08-04 | Prestwich Glenn D. | Preblocking with non-ha gags increases effectiveness of ha conjugated anticancer agents |
| AU2003267872A1 (en) * | 2002-05-06 | 2003-11-11 | University Of Utah Research Foundation | Preblocking with non-ha gags increases effectiveness of ha conjugated anticancer agents |
| US20080193372A1 (en) * | 2004-02-10 | 2008-08-14 | Barnes-Jewish Hospital | Efficacy and Safety of Targeted Particulate Agents with Decoy Systems |
| JP4543860B2 (ja) * | 2004-09-30 | 2010-09-15 | 株式会社島津製作所 | 試料の解析方法 |
| US20080004237A1 (en) * | 2006-02-23 | 2008-01-03 | Tam Joemy C | Polysacchocride prodrug of 5-fluorouracil (5-FU) with enhanced target specificity for galectin-3 expressing cancers |
| WO2012171035A1 (en) * | 2011-06-10 | 2012-12-13 | University Of Washington Through Its Center For Commercialization | Carbohydrate-based compositions and methods for targeted drug delivery |
| CN114377143A (zh) * | 2013-07-22 | 2022-04-22 | 康德乐健康414有限责任公司 | 用于诊断和治疗与表达cd206的细胞相关的病症的组合物、方法和药盒 |
| WO2016011419A1 (en) * | 2014-07-17 | 2016-01-21 | Ohio State Innovation Foundation | Compositions for targeting macrophages and other cd206 high expressing cells and methods of treating and diagnosis |
| CA2955438C (en) * | 2014-07-17 | 2024-07-02 | Ohio State Innovation Foundation | DEXTRANE CONJUGATES TO TARGET MACROPHAGES AND OTHER CELLS EXPRESSING THE D-MANBOSE BINDING TYPE C LECTIN RECEPTOR |
| WO2016118188A1 (en) * | 2015-01-21 | 2016-07-28 | Navidea Biopharmaceuticals, Inc. | Compositions for targeting macrophages and other mannose-binding c-type lectin receptor high expressing cells |
| MX2019004029A (es) * | 2016-10-07 | 2019-09-27 | Navidea Biopharmaceuticals Inc | Compuestos y metodos para diagnosis y tratamiento de infecciones virales. |
| CA3064277A1 (en) * | 2017-05-19 | 2018-11-22 | Navidea Biopharmaceuticals, Inc. | Cd206+ macrophage-specific molecular imaging probe compositions and methods and the noninvasive quantification of arterial wall macrophage infiltration in humans |
| WO2019018815A1 (en) * | 2017-07-21 | 2019-01-24 | Navidea Biopharmaceuticals, Inc. | USE OF 99MTC-TILMANOCEPT AND ASSOCIATED MOLECULAR CONSTRUCTS FOR THE IDENTIFICATION AND DIAGNOSIS OF MALIGNANT TUMORS, AND FOR THE MONITORING OF ANTI-TUMOR THERAPEUTIC INTERVENTIONS |
-
2020
- 2020-09-30 US US17/039,409 patent/US20210145989A1/en active Pending
- 2020-09-30 CN CN202080083041.5A patent/CN115151264B/zh active Active
- 2020-09-30 JP JP2022519804A patent/JP7599727B2/ja active Active
- 2020-09-30 WO PCT/US2020/053604 patent/WO2021067479A1/en not_active Ceased
- 2020-09-30 EP EP20872002.9A patent/EP4021459A4/en active Pending
- 2020-09-30 CA CA3155675A patent/CA3155675A1/en active Pending
- 2020-09-30 MX MX2022003699A patent/MX2022003699A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022550174A5 (https=) | ||
| Harrison et al. | Osteogenic sarcoma: systemic chemotherapy options for localized disease | |
| JP4056701B2 (ja) | 薬剤および診断薬の送達のための高分子担体 | |
| Moreno et al. | Reduction of advanced liver fibrosis by short‐term targeted delivery of an angiotensin receptor blocker to hepatic stellate cells in rats | |
| JP2020536845A5 (https=) | ||
| JP2025137626A5 (https=) | ||
| CN1635910A (zh) | 巨噬细胞介导的疾病的治疗和诊断 | |
| JP2002543111A (ja) | ポリマーを使用する葉酸で仲介された腫瘍細胞へのターゲッティングの増幅 | |
| JP2017507931A5 (https=) | ||
| JP2001515708A5 (https=) | ||
| AU2011301153B2 (en) | Companion animal treatments | |
| JPH09509966A (ja) | ヘモグロビンを基礎とした複合体による抗腫瘍療法の増強 | |
| JP2011528710A5 (https=) | ||
| JP2022537019A5 (https=) | ||
| JP2021514003A5 (https=) | ||
| ES2599032T3 (es) | Método de tratamiento y bioensayo que implica el factor de inhibición de la migración de macrófagos (MIF) como factor depresor del miocardio de origen cardiaco | |
| JP2025165975A5 (https=) | ||
| Takakura et al. | Lymphatic transport after parenteral drug administration | |
| JP2025501978A5 (https=) | ||
| WO2025237213A1 (zh) | 靶向型免疫耐受性疫苗及其制备方法与用途 | |
| JP2023510865A5 (https=) | ||
| Lindén et al. | A Novel Platform for Radioimmunotherapy: Extracorporeal Depletion of Biotinylated and90Y-Labeled Rituximab in Patients with Refractory B-Cell Lymphoma | |
| JP2011503203A5 (https=) | ||
| CN109125313B (zh) | 一种复合制剂及其在制备肿瘤治疗药物中的用途 | |
| Jákó et al. | IgE lambda monoclonal gammopathy and amyloidosis |